AsclepiX Therapeutics to Present at Solebury Trout Private Company Showcase on October 15, 2020

BALTIMORE, MD / ACCESSWIRE / October 13, 2020 / AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular homeostasis for the treatment of retinal and other important diseases, will present at the Fall Private Company Showcase hosted by Solebury Trout, BMO and Davis Polk which is being held virtually on October 15, 2020.

Asclepix is scheduled to present on October 15 at 3.40pm EST, with one-on-one meetings to be held throughout the conference. The Presentation will be webcast live and available for replay: https://www.webcaster4.com/Webcast/Page/2408/37749

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email jbalanova@soleburytrout.com

About AsclepiX Therapeutics, Inc.

AsclepiX Therapeutics Inc. is a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular homeostasis that is disrupted in retinal and oncologic diseases. The novel clinical candidate peptides discovered by AsclepiX tap into these naturally existing self-regulating mechanisms, evolved over millions of years, that the body uses to maintain homeostasis and thus restore and maintain health. AXT107, an investigational product and the lead clinical candidate, has a unique mechanism of action that targets two clinically proven pathways of diseases of the retina. The novel self-assembling gel depot that AXT107 forms upon injection into the vitreous, may reduce patient and caregiver burden patients by decreasing the number of treatment injections, potentially to only once every year. AXT107 is poised to enter the clinic in late 2020. Learn more at www.asclepix.com.

Investor contact:

AsclepiX Therapeutics: Julia Balanova, jbalanova@soleburytrout.com 646-378-2936

SOURCE: AsclepiX Therapeutics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/609859/AsclepiX-Therapeutics-to-Present-at-Solebury-Trout-Private-Company-Showcase-on-October-15-2020

Staff

Recent Posts

TempraMed Launches National Brick and Mortar Pharmacy Roll Out, Shipping Products to Maccabi Pharmacies Across Israel

Key Commercialization Milestone in Retail Pharmacy Network that Serves Over 2.8 Million Insured MembersVancouver, British…

1 hour ago

NuGen Medical Devices Inc. Provides Update on Health Canada License

Toronto, Ontario--(Newsfile Corp. - February 5, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"…

10 hours ago

Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026

Demonstrating Instantaneous Ablation Through High-Voltage Waveforms and Efficient Point-by-Point Pulsed Field AblationCARDIFF-BY-THE-SEA, Calif., Feb. 5,…

10 hours ago

LEADOPTIK Announces First-in-Human Use of FDA-Cleared LIA™ System

SAN JOSE, Calif., Feb. 5, 2026 /PRNewswire/ -- LEADOPTIK, Inc., a medical technology company focused…

10 hours ago

Dräger PSS® AirBoss SCBA Now Available for Purchase in North America

Now Available for Purchase, AirBoss Delivers an NFPA 1970:2025 SCBA Built for the Way American…

16 hours ago

Greenway Health® Named Most Improved Physician Practice Solution 2026 by KLAS Research

KLAS recognition highlights Greenway's momentum in modernizing physician practice technologyTAMPA, Fla., Feb. 5, 2026 /PRNewswire/…

16 hours ago